

JUNE 2024 | EDITION #8





Insel Gruppe AG University Hospital in Bern, Switzerland is using our state-of-the-art software.



Updates and Accolades

AJNR SCANTastic video showcases the benefits of IB Neuro



Excellent job Dr. Lea Alhilali, MD @ teachplaygrub on this video explaining perfusion imaging.

[View video](#)

- IB announces the successful deployment of its state-of-the-art software at Insel Gruppe AG in Bern, Switzerland. This installation was facilitated through Bayer's Calantic™ platform on which IB's exclusive algorithms are made available under a partnership agreement. Insel Gruppe AG is one of the longest-running university hospitals in Europe. It was founded in 1354 and has since become a leading medical institution, playing a pivotal role in medical education and training.
- A study, led by Siem Herings, from Radboud University Medical Center in Nijmegen, the Netherlands, validates the benefit of the company's IB Rad Tech workflow software for distinguishing treatment effect from tumor progression in post-treatment glioma patients. "We chose to use IB software for our study on perfusion analysis as it allowed for quantitative analysis of standardized perfusion metrics in whole glioma lesions while also being user-friendly." [Read article here](#)
- In 2012, Dr. Leland Hu correlated IB Neuro's DSC output with spatially matched tissue samples. This study was replicated by the Medical College of Wisconsin, incorporating standardized rCBV thresholds, which demonstrated greater consistency compared to normalized rCBV. An April article in AJNR demonstrates improved interreader agreement and confidence with IB's DSC-FTB maps. This article was nominated for the 2024 AJNR Journal Awards! [Read article here](#)
- Dr. Adrienne Dula, PhD, at The University of Texas Dell Medical School, will non-invasively investigate and quantify biological factors that account for sex differences in stroke. Dula's lab is working to create a neuroimaging repository of acute stroke clinical and imaging data. The data will allow evaluation at the population level to enable inter-subject comparison and geometric characterization of complex factors impacting the unique stroke risk. The study will utilize a customized IB Rad Tech workflow. IB is proud to collaborate on new and investigational research!



EXPANDED ACCESS PROGRAM UPDATE

Imaging Biometrics is proud to announce that we have secured approval from the FDA for an Expanded Access Program (EAP). The EAP is open to physicians whose patients have exhausted standard-of-care therapies and fit the eligibility criteria. This program is a beacon of hope for individuals in the United States battling brain tumors who were unable to partake in our initial clinical trial at MCW.

The EAP, commonly known as 'compassionate use,' provides experimental treatments to patients outside of clinical trials. Governed by the FDA, the program serves as a critical pathway for those with limited or no other treatment options, offering access to potentially promising therapies prior to regulatory approval.

Oral GaM has shown an impressive safety profile. Participants in the initial trial experienced no adverse effects and the convenience of taking GaM at home further enhances patient comfort and accessibility. Physicians and patients can find more information about this program under clinicaltrials.gov (NCT06404034) or by emailing eap@imagingbiometrics.com.




IB NIMBLE

We are excited to announce the adoption of IB Nimble at a prominent East Coast hospital. This significant milestone a step forward in enhancing patient care and clinical efficiency.

IB Nimble provides access to a set of professionally recognized diagnostic algorithms for diseases. It also allows asynchronous communication between clinical experts facilitating patient care. The handheld mobile app provides real-time, evidence-based treatment plans reducing length of hospital stay, costs, and care delays. [Watch the video here](#)

IB USER'S GROUP WEBINAR VIDEO




[View recording here](#)

TITLE:
Considerations For Accurate & Reliable DSC MRI

OBJECTIVE:
 IB Neuro streamlines DSC perfusion processing. Quantitative output can be computed automatically for direct longitudinal comparison. No need to manually draw normalizing ROIs!

PRESENTER:
 Melissa Prah
 Engineer II,
 Medical College of Wisconsin



The Musella Foundation

The Musella Foundation for Brain Tumor Research & Information, Inc. is a 501(c)(3) nonprofit public charity devoted to empowering brain tumor patients and their families. They provide emotional and financial support, facilitate educational resources, advocate for patients' needs, and strive to raise funds for groundbreaking brain tumor research. They have awarded over \$10 million (as of Oct 1, 2022) in direct patient assistance to help patients get the treatment they need! Together, we aim to make a difference in the lives of those affected by brain tumors and contribute to the advancement of effective treatments. [View the Musella Foundation Website](#)

SPOTLIGHT



LOOK FOR INVITES FOR THE NEXT USER GROUP WEBINAR IN SEPTEMBER.

FOLLOW US ON



https://twitter.com/iqai_ib



<https://www.linkedin.com/company/imaging-biometrics-llc>

13416 Watertown Plank Road
 Suite 260 | Elm Grove, WI 53122
 +1.262.439.8252
 email: info@imagingbiometrics.com